AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28429906 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-glutinous brown rice (BR)
Number of subjects: 37
Study 28429906 — intervention group
Group type: COMPARATOR
Intervention: Non-glutinous white rice (WR)
Number of subjects: 37
Study 26749760 — intervention group
Group type: EXPERIMENTAL
Intervention: Nobecutan® plastic dressing spray applied directly on the wound
Number of subjects: 82
Study 26749760 — intervention group
Group type: COMPARATOR
Intervention: No dressing spray applied (control group)
Number of subjects: 82
Study 23957658 — intervention group
Group type: EXPERIMENTAL
Intervention: Generx (Ad5FGF4) administered via intracoronary route
Number of subjects: 100
Study 23957658 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 21429975 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home visiting programme
Number of subjects: 208
Study 21429975 — intervention group
Group type: COMPARATOR
Intervention: Usual universal care
Number of subjects: 208
Study 19187190 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemophilia patients
Number of subjects: 83
Study 17276647 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 15258127 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) applied via large surface electrodes at an intensity sufficient to evoke 50% of maximal voluntary contraction (MVC) during an 80-Hz tetanus.
Number of subjects: 20
Study 15258127 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous stimulation (maximally to the femoral nerve).
Number of subjects: 20
Study 15258127 — intervention group
Group type: EXPERIMENTAL
Intervention: P20 and P80 measurements.
Number of subjects: 20
Study 15258127 — intervention group
Group type: EXPERIMENTAL
Intervention: P20-P80 ratio measurement.
Number of subjects: 20
Study 15258127 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-to-high frequency ratio measurement.
Number of subjects: 20
Study 15258127 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extensor MVC and voluntary activation level measurements.
Number of subjects: 20
Study 11164665 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (anabolic steroid)
Number of subjects: 2
Study 11164665 — intervention group
Group type: COMPARATOR
Intervention: Control (optimum nutrition and exercise alone)
Number of subjects: 2
Study 9333788 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline chewable tablet (100 mg)
Number of subjects: 14
Study 9333788 — intervention group
Group type: COMPARATOR
Intervention: Theophylline solution (reference)
Number of subjects: 14
Study 8492277 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplement (20 mg Fe) for 30 days
Number of subjects: 47
Study 8492277 — intervention group
Group type: EXPERIMENTAL
Intervention: Vermifuge treatment
Number of subjects: 47
Study 8492277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 3124628 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin
Number of subjects: 0
Study 3124628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2686393 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (D) alone (60 mg/m2, observation after 500 mg/m2)
Number of subjects: 185
Study 2686393 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (D) combined with Vincristine (V) and Mitomycin C (M) (D: 50 mg/m2, V: 1 mg/m2, M: 10 mg/m2, given every other cycle)
Number of subjects: 185
Study 2686393 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine (V) and Mitomycin C (M) following Doxorubicin (D) alone
Number of subjects: 185
Study 2686393 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (D) alone
Number of subjects: 185
Study 2686393 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (D) combined with Vincristine (V) and Mitomycin C (M)
Number of subjects: 185
Study 29940261 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg hydrocortisone
Number of subjects: 33
Study 29940261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 28623892 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based social worker stroke case management (SWSCM) program
Number of subjects: 214
Study 28623892 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of SWSCM program plus access to an online information and support resource (MISTT website)
Number of subjects: 214
Study 28623892 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 214
Study 26115976 — intervention group
Group type: EXPERIMENTAL
Intervention: carboplatin/docetaxel + celecoxib
Number of subjects: 196
Study 26115976 — intervention group
Group type: COMPARATOR
Intervention: carboplatin/docetaxel
Number of subjects: 196
Study 23228436 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy/Cognitive Behavior Therapy (MET/CBT)+Parent Management Training+Contingency Management (CM)
Number of subjects: 68
Study 23228436 — intervention group
Group type: COMPARATOR
Intervention: MET/CBT+Parent Drug Education (attention control)
Number of subjects: 68
Study 21727105 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesogenic control scale
Number of subjects: 1685
Study 21727105 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesogenic risk scale
Number of subjects: 1685
Study 21727105 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between control and risk scales
Number of subjects: 1685
Study 19727022 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease supplementation (5.83 g daily)
Number of subjects: 29
Study 19727022 — intervention group
Group type: COMPARATOR
Intervention: Cellulose placebo
Number of subjects: 29
Study 19727022 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease supplementation
Number of subjects: 29
Study 16919574 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress testing (technetium 99m methoxyisobutylisonitrile myocardial scintigraphy)
Number of subjects: 16
Study 16919574 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress testing
Number of subjects: 16
Study 16919574 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter monitoring
Number of subjects: 16
Study 16919574 — intervention group
Group type: COMPARATOR
Intervention: Physical or mental stress
Number of subjects: 16
Study 15273899 — intervention group
Group type: EXPERIMENTAL
Intervention: Rear-wheel position I
Number of subjects: 12
Study 15273899 — intervention group
Group type: EXPERIMENTAL
Intervention: Rear-wheel position II
Number of subjects: 12
Study 15273899 — intervention group
Group type: COMPARATOR
Intervention: Rear-wheel position I and II
Number of subjects: 12
Study 11724457 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary polyunsaturated fatty acid (PUFA) supplementation
Number of subjects: 0
Study 11724457 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9203116 — intervention group
Group type: EXPERIMENTAL
Intervention: Form 90 (structured interview for assessing alcohol treatment outcomes)
Number of subjects: 178
Study 8356998 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone (1,000-2,000 mg/day)
Number of subjects: 100
Study 8356998 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (100-200 mg/day)
Number of subjects: 100
Study 8356998 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam (10-20 mg/day)
Number of subjects: 100
Study 3112999 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental nursing home settings
Number of subjects: 41
Study 3112999 — intervention group
Group type: COMPARATOR
Intervention: Conventional long-stay wards
Number of subjects: 41
Study 29888715 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) group
Number of subjects: 25
Study 29888715 — intervention group
Group type: EXPERIMENTAL
Intervention: Different protocol of ozone therapy group
Number of subjects: 25
Study 29888715 — intervention group
Group type: COMPARATOR
Intervention: Ozone therapy group
Number of subjects: 25
Study 29888715 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study 26865200 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide prescription
Number of subjects: 7582
Study 26865200 — intervention group
Group type: EXPERIMENTAL
Intervention: Single agent prescription
Number of subjects: 7582
Study 26865200 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic factors
Number of subjects: 7582
Study 26865200 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney function
Number of subjects: 7582
Study 24285366 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior referencing (AR)
Number of subjects: 100
Study 24285366 — intervention group
Group type: COMPARATOR
Intervention: Posterior referencing (PR)
Number of subjects: 100
Study 22843306 — intervention group
Group type: EXPERIMENTAL
Intervention: Group V: Anesthesia induced with midazolam, remifentanil, propofol, and vecuronium; maintained with continuous infusion of propofol and remifentanil.
Number of subjects: 60
Study 22843306 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I: Anesthesia induced with midazolam, fentanyl, propofol, and vecuronium; maintained with inhaled isoflurane and intravenous bonus of fentanyl.
Number of subjects: 60
Study 22843306 — intervention group
Group type: COMPARATOR
Intervention: Group C: Anesthesia induced as in group I; maintained with isoflurane inhalation combined with propofol-remifentanil infusion.
Number of subjects: 60
Study 21051293 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA)
Number of subjects: 28
Study 21051293 — intervention group
Group type: COMPARATOR
Intervention: Plasmapheresis (PP)
Number of subjects: 28
Study 17029543 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2, Fuji Ortho LC without acid conditioning
Number of subjects: 15
Study 17029543 — intervention group
Group type: COMPARATOR
Intervention: Group 1, phosphoric acid + Fuji Ortho LC
Number of subjects: 15
Study 15740824 — intervention group
Group type: EXPERIMENTAL
Intervention: Estratab plus Prometrium
Number of subjects: 89
Study 15740824 — intervention group
Group type: EXPERIMENTAL
Intervention: Estratest
Number of subjects: 89
Study 15740824 — intervention group
Group type: EXPERIMENTAL
Intervention: Estratab plus Provera
Number of subjects: 89
Study 15740824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 15740824 — intervention group
Group type: COMPARATOR
Intervention: Estratab (primarily estrone)
Number of subjects: 89
Study 12850363 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal 9-valent PCV immunization
Number of subjects: 154
Study 12850363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 10418709 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo prompt gamma neutron activation analysis using a 252Cf neutron source, 40 min duration, mean whole-body equivalent dose of 0.25 mSv
Number of subjects: 13
Study 10418709 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid phantom measurements for long-term stability
Number of subjects: 13
Study 7730003 — intervention group
Group type: EXPERIMENTAL
Intervention: Health instruction provided by student nurses
Number of subjects: 285
Study 2203303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (62.5, 125, 250, 500, 1,000, or 2,000 mg as a 30‐min intravenous infusion)
Number of subjects: 24
Study 2203303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (250 to 2,000 mg)
Number of subjects: 24
Study 2203303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 24
Study 2203303 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 24
Study 6791201 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (AT) 50 mg
Number of subjects: 6
Study 6791201 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (AT) 100 mg
Number of subjects: 6
Study 6791201 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT)
Number of subjects: 6
Study 6791201 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (AT) with a large, fatty meal
Number of subjects: 6
Study 6791201 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (AT) leading to Nortriptyline (NT) production
Number of subjects: 6
Study 6791201 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (AT)
Number of subjects: 6
Study 30679095 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral insulin 338 (I338)
Number of subjects: 50
Study 30679095 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin glargine (IGlar)
Number of subjects: 50
Study 29930798 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic treatment, administered two times a week for two weeks.
Number of subjects: 200
Study 29930798 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 200
Study 27349944 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 79
Study 27349944 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 79
Study 24335157 — intervention group
Group type: EXPERIMENTAL
Intervention: ICDAS II + LAA
Number of subjects: 140
Study 24335157 — intervention group
Group type: COMPARATOR
Intervention: Nyvad
Number of subjects: 140
Study 22110048 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 30
Study 22110048 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 30
Study 19494215 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC207 (400 mg daily for 2 weeks, followed by 200 mg three times a week for 6 weeks)
Number of subjects: 47
Study 19494215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 17484523 — intervention group
Group type: EXPERIMENTAL
Intervention: Bach's Magnificat during physiotherapy treatment
Number of subjects: 40
Study 17484523 — intervention group
Group type: COMPARATOR
Intervention: Control group (physiotherapy only)
Number of subjects: 40
Study 15064016 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO), n = 39, given orally at a dose of 0.45 g/m(2) 4 hours prior to radiation treatment and during brachytherapy (40Gy)
Number of subjects: 73
Study 15064016 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P), n = 34, given in addition to radiotherapy
Number of subjects: 73
Study 15064016 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO)
Number of subjects: 73
Study 15064016 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 73
Study 11430843 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative therapy using approved drugs for unapproved purposes
Number of subjects: 0
Study 11430843 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 11430843 — intervention group
Group type: COMPARATOR
Intervention: Active treatments in controlled trials
Number of subjects: 0
Study 9535316 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 376
Study 7648803 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (30 mg d‐1 for initial 3 months)
Number of subjects: 159
Study 7648803 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular clinic visits
Number of subjects: 159
Study 7648803 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural group therapy
Number of subjects: 159
Study 7648803 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined home and clinic visits
Number of subjects: 159
Study 7648803 — intervention group
Group type: COMPARATOR
Intervention: Control group (58 patients)
Number of subjects: 159
Study 2501593 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO (D,L-alpha-difluoromethylornithine) administered orally at a dose of 1.7 g/sq.m. t.i.d.
Number of subjects: 38
Study 2501593 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy without DFMO
Number of subjects: 38
Study 778456 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fructose (1000 cc of 10% fructose)
Number of subjects: 20
Study 778456 — intervention group
Group type: COMPARATOR
Intervention: Intravenous glucose (10% glucose)
Number of subjects: 20
Study 30733167 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cognitive assessments
Number of subjects: 104
Study 28438539 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (5 mg/kg/d) 3 d/wk for 12 months
Number of subjects: 40
Study 28438539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28438539 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 40
Study 26224129 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin (BLF)
Number of subjects: 130
Study 26224129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 23474153 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacerein 50 mg BID for 12 weeks
Number of subjects: 86
Study 23474153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 22379922 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment maneuver
Number of subjects: 0
Study 20085679 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir 400 mg three times daily from 36 weeks' gestation
Number of subjects: 27
Study 17699214 — intervention group
Group type: COMPARATOR
Intervention: Ramipril + spironolactone placebo + irbesartan placebo
Number of subjects: 41
Study 17699214 — intervention group
Group type: COMPARATOR
Intervention: Ramipril + irbesartan + spironolactone placebo
Number of subjects: 41
Study 17699214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril + irbesartan placebo + spironolactone
Number of subjects: 41
Study 17699214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril + irbesartan + spironolactone
Number of subjects: 41
Study 15657468 — intervention group
Group type: EXPERIMENTAL
Intervention: HGlu (glucose)
Number of subjects: 10
Study 15657468 — intervention group
Group type: EXPERIMENTAL
Intervention: HMal (maltose)
Number of subjects: 10
Study 15657468 — intervention group
Group type: EXPERIMENTAL
Intervention: MalMix (sucrose, maltose, and maltodextrin)
Number of subjects: 10
Study 15657468 — intervention group
Group type: COMPARATOR
Intervention: Plac (placebo)
Number of subjects: 10
Study 15657468 — intervention group
Group type: EXPERIMENTAL
Intervention: MalMix
Number of subjects: 10
Study 15657468 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate drinks (HGlu, HMal, MalMix)
Number of subjects: 10
Study 11350782 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion to achieve moderate (approximately 75 pmol/l) and high (approximately 150 pmol/l) physiological insulin levels during hyperinsulinemic‐hyperglycemic clamps.
Number of subjects: 28
Study 9266778 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine therapy for 10 days
Number of subjects: 7
Study 9266778 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 7
Study 9266778 — intervention group
Group type: COMPARATOR
Intervention: Control test
Number of subjects: 7
Study 7743568 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia (LA)
Number of subjects: 202
Study 7743568 — intervention group
Group type: COMPARATOR
Intervention: Caudal anaesthesia (CA)
Number of subjects: 202
Study 2352468 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of fentanyl 0.001%
Number of subjects: 40
Study 2352468 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.001% mixed with bupivacaine 0.1%
Number of subjects: 40
Study 2352468 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of fentanyl 0.0005%
Number of subjects: 40
Study 2352468 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.0005% mixed with bupivacaine 0.1%
Number of subjects: 40
Study 2352468 — intervention group
Group type: COMPARATOR
Intervention: Control group (fentanyl 0.0005%)
Number of subjects: 40
Study 2352468 — intervention group
Group type: COMPARATOR
Intervention: Control group (fentanyl 0.0005% mixed with bupivacaine 0.1%)
Number of subjects: 40
Study 2352468 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 40
Study 6163292 — intervention group
Group type: EXPERIMENTAL
Intervention: Candle-jar system for direct inoculation in culture diagnosis of gonorrhoea
Number of subjects: 0
Study 6163292 — intervention group
Group type: COMPARATOR
Intervention: Conventional system using Stuart transportation medium and inoculation in the laboratory
Number of subjects: 0
Study 30600490 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Exercise Program (MEXP)
Number of subjects: 14
Study 30600490 — intervention group
Group type: COMPARATOR
Intervention: Stretching (Control)
Number of subjects: 14
Study 28078530 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 5% medicated plaster, applied as one or three simultaneous plasters
Number of subjects: 0
Study 26095558 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic cholecystectomy (SP)
Number of subjects: 110
Study 26095558 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-port laparoscopic cholecystectomy (FP)
Number of subjects: 110
Study 26095558 — intervention group
Group type: COMPARATOR
Intervention: Follow-up for >1 year
Number of subjects: 110
Study 23334675 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/day
Number of subjects: 699
Study 23334675 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 25 mg/day
Number of subjects: 699
Study 23334675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 699
Study 21834921 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 and omega-6 fatty acids supplementation (3 capsules daily)
Number of subjects: 138
Study 21834921 — intervention group
Group type: COMPARATOR
Intervention: Placebo containing medium-chain triglycerides
Number of subjects: 138
Study 19567409 — intervention group
Group type: EXPERIMENTAL
Intervention: Piboserod 80 mg for 24 weeks
Number of subjects: 137
Study 19567409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 17352805 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative biliary drainage (for 4 weeks)
Number of subjects: 210
Study 17352805 — intervention group
Group type: COMPARATOR
Intervention: Early surgical treatment (within one week)
Number of subjects: 210
Study 15476525 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 0